Image For Activity Cover
Cardiovascular Protection in PAD and Post-PCI: Planning Beyond the Revascularization
Faculty and Program
Eric Secemsky, MD, MSc, FSCAI
Atherothrombotic Risk Reduction in CAD, PAD, or Both 
Sandeep Nathan, MD, MSc, FSCAI
Case 1: Polyvascular Disease Patient: S/P Multivessel CAD PCI and New Diagnosis of PAD 
Marc Bonaca, MD, MPH  
PAD and PVI Pharmacotherapy 
Dmitriy N. Feldman, MD, FSCAI 
Case 2: PAD Patient Undergoing Lower Extremity PVI for CLTI 
Learning Objectives
Upon completion of this activity, participants will be able to:
  • Discuss the residual risk for atherothrombotic events, stroke and vascular death in patients with CAD, PAD or both
  • Interpret the contemporary data on combined therapy with aspirin and DOAC in patients with polyvascular disease
  • Optimize the balance of bleeding risk and antithrombotic benefit in patients with PAD who underwent peripheral revascularization
  • Assess the interplay of patient-specific factors (e.g. type and timing of revascularization, comorbidities, concomitant medications) and antithrombotic therapy
Acknowledgement of Commercial Support

This activity is sponsored by SCAI and supported by Janssen.

Continuing Education Information
This activity is not certified for accredited continuing education.
© 2022-2023 Society for Cardiovascular Angiography and Interventions (SCAI). All rights reserved.
Availability: On-Demand
Cost: FREE
Credit Offered:
No Credit Offered
Powered By